Lung Cancer

Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis

Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis

[OncoTargets and Therapy] This meta-analysis assesses the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer.

Lung Cancer Screening: Risk-Targeting Approach vs NLST Eligibility Criteria

Lung Cancer Screening: Risk-Targeting Approach vs NLST Eligibility Criteria

In a review of data from the NLST, researchers sought to determine if a risk-targeting approach would more efficiently select high-risk persons for lung cancer screening than the eligibility criteria defined by the NLST.

Platinum-Based Chemotherapies Demonstrate Similar Risk for Thromboembolic Events

Platinum-Based Chemotherapies Demonstrate Similar Risk for Thromboembolic Events

Platinum-based chemotherapy agents for lung cancer may increase the risk for thromboembolism.

Documentation of Cancer Risk in Indeterminate Pulmonary Nodules Inconsistent

Documentation of Cancer Risk in Indeterminate Pulmonary Nodules Inconsistent

By

Qualitative risk statements of malignancy for indeterminate pulmonary nodules are imprecise, highly variable, and should be replaced by a standard scale.

Lung Cancer Screening More Efficient for Those at Higher Risk

Lung Cancer Screening More Efficient for Those at Higher Risk

Initial screens were least effective and least efficient for veterans with lowest lung cancer risk, according to this study.

Nearly One Third of Veterans Report Current Tobacco Use

Nearly One Third of Veterans Report Current Tobacco Use

Researchers found that nearly one third of veterans reported current use of a tobacco product, with cigarettes being most frequently used.

Risk-based lung cancer screening may prevent more deaths than current guidelines

1. In terms of early lung cancer death per individual screened, targeting lung cancer mortality risk may improve lung cancer screening efficiency. 2. However, the increases in efficiency were attenuated when measured by life-years, quality-adjusted life-years (QALYs), and cost-effectiveness. Evidence Rating Level: 2 (Good)          Study Rundown: Current guidelines for lung cancer screening using low-dose computed []

Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial

1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC). 2. Osimertinib treated patients had fewer grade 3 or higher adverse events compared to patients treated with standard EGFR-TKI therapy. []

Monetary Incentives Improve Quit Attempts in Mentally Ill Smokers

Monetary Incentives Improve Quit Attempts in Mentally Ill Smokers

Abstinence-contingent incentives improved smoking cessation outcomes among economically disadvantaged smokers with mental illness.

Pain Tolerance Lower in Abstinent Smokers Before, Following Surgery

Pain Tolerance Lower in Abstinent Smokers Before, Following Surgery

By

Abstinent smokers may have reduced preoperative pain tolerance and increased postoperative opioid use compared with nonsmokers.

Smoking Quit Rates Not Improved With Use of Pharmaceutical Cessation Aids

Smoking Quit Rates Not Improved With Use of Pharmaceutical Cessation Aids

By

Using data from the TUS-CPS, researchers sought to determine the effect of pharmaceutical smoking cessation aids on long-term quit rates among patients who smoke tobacco.

Surgery May Be Superior to Stereotactic Body RT for Early Stage Non-small Cell Lung Cancer

Surgery May Be Superior to Stereotactic Body RT for Early Stage Non-small Cell Lung Cancer

By

SBRT provides excellent local control and an adequate safety profile, but there is a lack of data comparing SBRT to resection among patients eligible for surgery.

Nab-paclitaxel/carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy

Nab-paclitaxel/carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy

[Lung Cancer: Targets and Therapy] Researchers examine the affect of first-line nab-paclitaxel plus carboplatinon QoL for patients with advanced non-small cell lung cancer.

Gefitinib Adjuvant Therapy Prolonged Disease-Free Survival in EGFR-Mutant NSCLC

Gefitinib Adjuvant Therapy Prolonged Disease-Free Survival in EGFR-Mutant NSCLC

By

Results of this randomized, phase 3 study comparing oral gefitinib with IV vinorelbine plus cisplatin revealed the effect of these regimens on disease-free survival in patients with exon 19 deletion or exon Leu585Arg NSCLC.

Liquid Biopsies: An Emerging and Versatile Monitoring Modality in Lung Cancer

Liquid Biopsies: An Emerging and Versatile Monitoring Modality in Lung Cancer

By

In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.

Alectinib Granted FDA Approval as First-line Therapy for <i>ALK</i>-positive NSCLC

Alectinib Granted FDA Approval as First-line Therapy for ALK-positive NSCLC

By

Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.

Cause of Death More Likely to Be Lung Cancer Than AIDS in Smokers With HIV

Cause of Death More Likely to Be Lung Cancer Than AIDS in Smokers With HIV

By

Populating a microsimulation of model of HIV disease, researchers investigated the the likelihood of lung cancer-related morbidity and mortality among patients with HIV who smoke, based on smoking intensity.

Netupitant Plus Palonosetron Safe, Effective Strategy for CINV in Lung Cancer

Netupitant Plus Palonosetron Safe, Effective Strategy for CINV in Lung Cancer

By

A post-hoc analysis of 2 clinical trials was conducted to determine the safety and effectiveness of NEPA for managing CINV in patients with lung cancer who received platinum-based chemotherapy.

Yoga Programs May Improve Quality of Life for Patients with NSCLC and Their Caregivers

Yoga Programs May Improve Quality of Life for Patients with NSCLC and Their Caregivers

By

This study evaluated the feasibility and potential efficacy of a yoga intervention for patients with NSCLC and their caregivers.

Language Barrier, Patient Ethnicity Do Not Delay Hospital Treatment in NSCLC

Language Barrier, Patient Ethnicity Do Not Delay Hospital Treatment in NSCLC

By

Impact of language barrier and patient ethnicity on time interval from diagnosis to treatment for patients with NSCLC was measured at a public hospital and a private hospital.

A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer

A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer

By

In this case, a female patient with advanced lung cancer experiences a rare episode of nivolumab-induced Herzmyasthenie, emphasizing the need to be aware of the potential for rapid myocarditis concomitant with MG in patients undergoing treatment with anti-PD-1 monoclonal antibodies.

Novel Predictive Model More Effectively Identifies Risk for Lung Cancer

Novel Predictive Model More Effectively Identifies Risk for Lung Cancer

By

PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC

By

Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.

Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy

Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy

[Lung cancer: Targets and Therapy] This research examines clinical data from Phase I-III trials of osimertinib, discusses mechanisms of resistance to osimertinib, and provides an outlook for the use of osimertinib and novel therapeutic combinations to improve EGFR-mutated NSCLC outcomes.

Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing

Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing

By

Combining radiotherapy and immunotherapy has shown early promise against some advanced cancers, but oncology nurses need to be wary of potential overlapping toxicity profiles from each of these treatment modalities.

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

By

Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.

Spontaneous Tumor Lysis Syndrome in Recently Diagnosed Small Cell Lung Cancer

Spontaneous Tumor Lysis Syndrome in Recently Diagnosed Small Cell Lung Cancer

By

This case demonstrates that, although rare, spontaneous TLS can occur even in the absence of chemotherapy, and a high index of suspicion for the effect should be maintained when patients with malignancies demonstrate the classic symptom of laboratory abnormalities.

FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

By

Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.

Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC

Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC

By

Patients with stage III NSCLC have a poor median PFS of 8 months despite achieving a good response to the current standard of care of platinum-based double chemotherapy with concurrent radiotherapy.

E-Cigarettes Increase BP, Heart Rate, Arterial Stiffness

E-Cigarettes Increase BP, Heart Rate, Arterial Stiffness

Significant increases seen in heart rate and arterial stiffness were observed in the first 30 minutes after smoking electronic-cigarette containing nicotine.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs